1257641-95-4

Upstream product

• 481701-70-6 benzyl 3-methoxy-4-benzyloxycinnamate 
• 1135-24-6 3-(4-hydroxy-3-methoxyphenyl)acrylic acid 
• 66074-00-8 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 
• 77795-22-3 4-benzyloxy-3-methoxycinnamic acid 
• 42381-67-9 (2E)-3-{4-[(ethoxycarbonyl)oxy]-3-methoxyphenyl}acrylic acid 
• 1135-24-6 (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid 
• 1257642-17-3 (E)-2-(4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yloxy)ethyl 3-(4-(ethoxycarbonyloxy)-3-methoxyphenyl)acrylate 

Relevant academic research and scientific papers

Phenylsulfonylfuroxan NO-donor phenols: Synthesis and multifunctional activities evaluation

Phenylsulfonyfuroxan nitric oxide (NO)-donor phenols were designed, synthesized and evaluated. The compounds were designed through a symbiotic approach using selected phenols and phenylsulfonylfuroxan NO-donor. The antioxidant activities of the hybrid compounds T2–T6 showed to be good in vivo. Compounds T4 and T6 revealed excellent yeast α-glucosidase inhibitory activity and anti-glycosylation activity. All of the compounds exhibited strong NO releasing activity and significant anti-platelet aggregation activity. The inhibition of platelet aggregation was more than 50% at low concentration (1.5?μM) and 95% at higher concentration (15?μM and 150?μM). The vasodilatation experiment demonstrated that the six compounds under test exhibited definite vasodilation activity (pIC50 ranged from 5.698 to 6.383), especially compound T6 (pIC50 was 6.383) which was similar to sodium nitroprusside (pIC50 was 6.786). Both anticoagulant and vasodilatation effects were correlated with their NO releasing activities. These hybrid phenylsulfonyfuroxan-based NO-donor phenols offer a multifunctional prodrug design concept for the development of therapeutic or preventive agents for metabolic syndrome.

Design and synthesis of novel NO-donor-ferulic acid hybrids as potential antiatherosclerotic drug candidates a

Novel NO-donor-ferulic acid hybrids were designed and synthesized through a symbiotic approach using ferulic acid and three different NO-donating groups, such as nitric ester, 4-hydroxyl-3-phenylfuroxan, and 4-hydroxymethyl-3- phenylsulfonylfuroxan. Antioxidant, nitric oxide release, and vasodilator properties studies showed that the target phenylsulfonylfuroxan 14, especially 14c, while keeping the antioxidant activity, showed more NO release activity and vasodilating activity than isosorbide dinitrate (ISDN). Thus, 14c may be considered a novel potent anti-atherosclerosis drug candidate.